First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany

Kuhr Kathrin; Wirth Daniel; Srivastava Kunal; Lehmacher Walter; Hellmich Martin

首页> 外文期刊>European journal of clinical pharmacology >First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany

【24h】

First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany

机译：对非移植性多发性骨髓瘤患者的一线治疗：德国现有市场上治疗方案的直接和调整后间接比较

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The purpose of this study was to compare approved first-line therapies for patients with multiple myeloma.

机译：这项研究的目的是比较多发性骨髓瘤患者的一线治疗方案。

著录项

来源
《European journal of clinical pharmacology》 |2016年第3期|共9页
作者
Kuhr Kathrin; Wirth Daniel; Srivastava Kunal; Lehmacher Walter; Hellmich Martin;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Multiple myeloma; First-line therapy; Meta-analysis; Adjusted indirect treatment comparison;

机译：多发性骨髓瘤;一线治疗;Meta分析;调整后的间接治疗比较;

相似文献

外文文献
中文文献
专利

1. 索拉非尼与舒尼替尼一线治疗中国转移性肾细胞癌患者的疗效、安全性和生活质量的比较 [J] . Wen Cai, Wen Kong, Baijun Dong, 癌症（英文版） . 2018,第003期
2. First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany [J] . Kuhr Kathrin, Wirth Daniel, Srivastava Kunal, European journal of clinical pharmacology . 2016,第3期

机译：对非移植性多发性骨髓瘤患者的一线治疗：德国现有市场上治疗方案的直接和调整后间接比较
3. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Lowa??Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison [J] . Suzy Van Sanden, Tetsuro Ito, Joris Diels, The oncologist . 2018,第3期

机译：Daratumumab单药治疗和Pomalidomide联合Lowa ??剂量地塞米松治疗多发性骨髓瘤的疗效比较：调整后的间接比较
4. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison [J] . Van Sanden Suzy, Ito Tetsuro, Diels Joris, The oncologist . 2018,第3期

机译：甘肃宫单药治疗和吡米胺加低剂量地塞米松治疗多发性骨髓瘤的比较疗效：匹配调整的间接比较
5. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
6. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
7. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low‐Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison [O] . Suzy Van Sanden, *, Tetsuro Ito, 2018

机译：Daratumumab单药治疗和Pomalidomide联合小剂量地塞米松治疗多发性骨髓瘤的疗效比较：调整后的间接比较
8. PCN21 First-Line Therapy for Patients With Multiple Myeloma: Direct and Indirect Comparison of Treatment Regimens on the Existing Market [O] . Kuhr K., Wirth D., Srivastava K., 2014

机译：多发性骨髓瘤患者的PCN21一线治疗：现有市场上治疗方案的直接和间接比较

First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany

摘要

著录项

相似文献

相关主题

期刊订阅